報價延遲最少15分鐘:2025/07/05 09:51 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
129.11 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
2.95/6.06
|
|
企業價值
13.26B
|
| 資產負債 |
|
每股賬面淨值
25.62
|
| 現金流量 |
|
現金流量率
0.04
|
| 損益表 |
|
收益
2.36B
|
|
每股收益
18.03
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/05 09:51 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. |